Australia's notifiable diseases status, 1999: Annual report of the National Notifiable Diseases Surveillance System

This article published in Communicable Diseases Intelligence Volume 25, No 4, November 2001 contains the 1999 annual report of National Notifiable Diseases Surveillance System. This annual report is available as 32 HTML documents and is also available in PDF format.

Page last updated: 17 December 2001

A print friendly PDF version is available from this Communicable Diseases Intelligence issue's table of contents.


Appendix 1 - Case Definitions



The following table displays the case definitions for quarantinable diseases notified to the National Notifiable Diseases Surveillance System in 1999. If you are not able to access these data please e-mail cdi.editor@health.gov.au

Appendix 1c. Case definitions and ICD-10 code for notifiable diseases reported to NNDSS in 1999, quarantinable diseases

Disease
Case definition (NHMRC 1994)
ICD-10 code(s)
Cholera An illness characterised by diarrhoea and/or vomiting

AND isolation of toxigenic Vibrio cholerae serogroup O1 or O139 from a clinical sample

AO0
Plague A four-fold or greater change in serum antibody titre for Yersinia pestis

OR isolation of Yersinia pestis from a clinical specimen

A20
Rabies Clinically compatible neurological illness

AND either detection of rabies viral antigens in tissue

OR isolation of rabies virus from saliva, skin snips, CSF or neural tissue

A82
Viral haemorrhagic fever Sudden or insidious onset of fever, nausea, vomiting, diarrhoea, multifocal haemorrhages and shock. An appropriate travel history to an endemic country is supportive of diagnosis

AND one of the following: demonstration of specific IgM antibody by ELISA, IFA or Western blot

OR isolation of the virus in cell culture

OR demonstration of viral antigen in a tissue specimen to Ebola virus, Lassa fever virus, Marburg virus or Crimean Congo virus.

A96, A98, A99
Yellow fever A clinically compatible illness

AND demonstration of yellow fever virus, antigen or genome in any clinical specimen

OR a four-fold or greater change in serum antibody titre to yellow fever virus,

OR a single elevated yellow fever specific IgM antibody titre, where cross-reaction with other flaviviruses has been ruled out and the patient has not received yellow fever vaccine during the previous 2   months

A95


This article was published in Communicable Diseases Intelligence Volume 25, No 4, November 2001.

In this section

CDI Search

Search Communicable Diseases Intelligence

Communicable Diseases Intelligence subscriptions

Sign-up to email updates: Subscribe Now

Communicable Diseases Surveillance

This issue - Vol 25, No 4, November 2001

NNDSS 1999 Annual Report

Communicable Diseases Intelligence